Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-08-18
2009-10-06
Crouch, Deborah (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093100
Reexamination Certificate
active
07598228
ABSTRACT:
A prophylactic or therapeutic method for a disease associated with decreased expression of AOP-1 gene or AOP-1, comprising (1) transfecting a nucleic acid encoding AOP-1 or a nucleic acid encoding a polypeptide having an addition, deletion or substitution of one or more amino acids as compared with the amino acid sequence of AOP-1 while retaining the function of AOP-1, or (2) administering a material enhancing the expression of AOP-1 gene, a material enhancing the production of AOP-1 or a material enhancing the function of AOP-1.
REFERENCES:
patent: 6034250 (2000-03-01), Goldstein et al.
patent: 503582 (1992-09-01), None
patent: 515995 (1992-12-01), None
patent: 768314 (1997-04-01), None
patent: WO 95/04041 (1995-02-01), None
patent: WO 99/53917 (1999-10-01), None
patent: WO 00/55174 (2000-09-01), None
Hajjar, RJ et al. Circ Res 86:616-621, 2000.
Adams, AK et al. Am Fam Physician 60(3):895-904, 1999.
Hajjar, RJ et al. PNAS 95:5251-5256, 1998.
del Monte, F et al. Circulation 104:1424-1429, 2001.
Matsushima, S et al. Circulation 113:1779-1786, 2006.
Chirmule, N et al. Gene Therapy 6:1574-1583, 1999.
Sutherland FJ and DJ Hearse. Pharmacol Res 41(6):613-627, 2000.
Skrzypiec-Spring, M et al. J Pharmacol Toxicol Methods 55:113-126, 2007.
Kennell, DE. Progr Nucl Acid Res Mol Biol 11:259-301, 1971.
Nemoto, Y et al. Gene 91(2):261-265, 1990; abstract only.
Bryk, R. et al., “Peroxynitrite reductase activity of bacterial peroxiredosins”,Nature(2000), vol. 407, No. 6801, pp. 211-215.
Matsumoto, Akio et al., “Cloning of the peroxiredoxin gene family in rats and characterization of the fourth member”,FEBS Letters(1999), vol. 443, No. 3, pp. 246-250.
Nemoto, Y. et al., “Antisense RNA of the latent period gene (MER5) inhibits the differentiation of murine erythroleukemia cells”,Gene(1990), vol. 91, No. 2, pp. 261-265.
Tsuji, K. et al., Mammalian antioxidant protein complements alkylhydroperoxide reductase (ahpC) mutation inEscherichia coli., Biochem. J. (1995), vol. 307, No. Pt. 2, pp. 377-381.
Watabe, S. et al., “Purification and characterization of a substrate protein for mitochondrial ATP-dependent protease in bovine adrenal cortex”,J. Biochem. (1994), vol. 115, No. 4, pp. 648-654.
Yamamoto, T. et al., “Cloning of a housekeeping-type gene (MER5) preferentially expressed in murine erythroleukemia cells”,Gene(1989), vol. 80, No. 2, pp. 337-343.
Tatewaki, Masuo, “Ketsueki Kansaibo no Zoshoku to Bunka”,Chem. Abstr. (1992), vol. 117, (Columbus, OH) [English translation of excerpts].
Tatewaki, Masuo, “Sekkekkyu Bunka no Yudo”,Chem. Abstr. (1995), vol. 122, (Columbus, OH) [English translation of excerpts].
Furuya Mayumi
Hattori Fumiyuki
Sugimura Keijiro
Asubio Pharma Co. Ltd.
Crouch Deborah
Hunton & Williams LLP
Noble Marcia S
LandOfFree
Therapeutic methods and agents for diseases associated with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic methods and agents for diseases associated with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic methods and agents for diseases associated with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4134575